NSE: LUPIN | BSE: 500257

Falling Comet

Download real time

1971.05 -124.65 (-5.95%)

High volume+loss today

NSE 04 Apr, 2025 3:31 PM (IST)

89,991.2

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Acquisition

Lupin's subsidiary acquires UK-based Renascience Pharma for Rs 135 crore See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

05 Aug 2022, 12:00AM

1971.05

-5.95%

Rationalisation of US portfolio impacted Q1

Sell: Lupin Ltd.

Recommendation Target

ICICI Securities Limited

Lupin’s Q1FY23 performance was disappointing on profitability front. It reported its worst-ever EBITDA margin of 6.2% (I-Sec: 7.3%) due to restructuring in the US as well as continuous impact of inflation on raw materials and freight. US revenue sharply declined to US$121mn (I-Sec: 180mn) vs US$172/181mn YoY/QoQ on ~US$40-50mn one-time impact of restructuring, inventory write-offs and withdrawal of products.

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Lupin Ltd.

04 Aug 2022, 12:00AM

1971.05

-5.95%

Outlook hinges on niche approvals/cost minimization

Neutral: Lupin Ltd.

Target

Motilal Oswal

Number of FII/FPI investors increased from 925 to 964 in Dec 2024 qtr.

Lupin Ltd.

23 May 2022

1971.05

-5.95%

Result Update:Lupin

Hold: Lupin Ltd.

Target

Axis Direct

We maintain our HOLD rating on the stock with a revised TP of Rs 670/share.

Lupin Ltd. average weekly volume is high.

Lupin Ltd.

22 May 2022

1971.05

-5.95%

Lupin (SELL): Operationally poor quarter; further weighed down by one-offs

Sell: Lupin Ltd.

Target

BOB Capital Markets Ltd.

LPC booked a loss of Rs. 5.2 bn in Q4 with weak operating performance and contraction in margins, EBITDA was ~50% below consensus

Lupin Ltd.'s price crossed below 50Day SMA today

Lupin Ltd.

21 May 2022

1971.05

-5.95%

Lupin

Buy: Lupin Ltd.

Sharekhan

Lupin Ltd. is trading at high volume of 3.1M with price loss of -5.95.

Lupin Ltd.

20 May 2022

1971.05

-5.95%

Lupin Ltd

Hold: Lupin Ltd.

ICICI Direct

Lupin Ltd. is trading at high volume of 3.1M with price loss of -5.95.

Lupin Ltd.

09 Feb 2022

1971.05

-5.95%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company specializes in branded and generic formulations, API's and advanced drug delivery systems in the area of biotechnology. The...

Lupin Ltd.'s price crossed below 50Day SMA today

Lupin Ltd.

07 Feb 2022

1971.05

-5.95%

Result Update:Lupin

Hold: Lupin Ltd.

Recommendation Target

Axis Direct

We expect a near-term headwind for Lupin and therefore recommend a HOLD rating with a target price of Rs 950.

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Lupin Ltd.

05 Feb 2022, 12:00AM

1971.05

-5.95%

Lupin (SELL): Major benefits remain back ended, 3Q disappoints

Sell: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q3 revenue growth modest at 4% YoY (+2% QoQ) despite strong US and India formulation business, as API revenue declined 25%

Lupin Ltd.'s price crossed below 50Day SMA today

Lupin Ltd.

05 Feb 2022, 12:00AM

1971.05

-5.95%

Niche launches and cost optimization key to a turnaround

Neutral: Lupin Ltd.

Target

Motilal Oswal

3QFY22 miss led by business mix and lower operating leverage LPC delivered a lower than expected 3QFY22 financial performance, led by moderate growth in the US and India and higher price erosion and raw material cost. While the management continues its efforts towards building a complex pipeline and working on cost optimization measures, a meaningful benefit is expected from 2HFY23 onwards. We have cut our FY22E/FY23E/FY24E EPS estimate by 12%/26%/23% to reflect: a) lower offtake of seasonal products in the US, b) reduced demand...

Lupin Ltd. is trading at high volume of 3.1M with price loss of -5.95.

No results found

Is Lupin Ltd. worth buying?

907 Votes:

Buy 72.66%

Sell 17.64%

Hold 9.7%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf